Deadline approaching for MoonLake Immunotherapeutics (MLTX) shareholders who have incurred financial losses
Investors who have purchased or acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) common stock between March 10, 2024, and September 29, 2025, are reminded by Glancy Prongay & Murray LLP of the upcoming December 15, 2025, deadline to file a lead plaintiff motion in the class action. This opportunity is for investors who incurred losses on their MoonLake investments. The firm draws attention to the disappointing Phase 3 results disclosed by MoonLake Immunotherapeutics on September 28, 2025. The results pertained to their sole drug candidate, sonelokimab (“SLK”), which failed to demonstrate efficacy comparable to Union Chimique Belge’s bimekizumab-bkz (“BIMZELX”).
The company had positioned SLK’s nanobody structure as superior to other monoclonal antibodies, claiming advantages that were not proven. However, the revelation that SLK targeted the same molecules and did not exhibit any proven benefits led to a significant decline in MoonLake’s stock price. Subsequently, the stock plummeted by 89.9%, closing at $6.24 per share on September 29, 2025, causing substantial losses for investors.
The class action lawsuit filed against MoonLake alleges that during the Class Period, the defendants made false and misleading statements about the company’s business, operations, and prospects. It is claimed that MoonLake failed to disclose crucial facts to investors. Notably, they did not reveal that SLK and BIMZELX targeted the same inflammatory cytokines, rendering SLK’s distinct Nanobody structure ineffective in providing superior clinical benefits. Moreover, the supposed advantage of SLK’s increased tissue penetration did not translate into clinical efficacy as asserted by the company. As a result, the positive statements made by the defendants concerning MoonLake’s business were considered misleading and lacked a reasonable basis throughout the relevant period.
Investors who have purchased MoonLake common stock within the Class Period are encouraged to take action by December 15, 2025, to seek appointment as lead plaintiff in the lawsuit. For those interested in learning more about the case or have questions regarding their rights, they are advised to reach out to Glancy Prongay & Murray LLP. Contact information is as follows: Charles Linehan, Esq., Glancy Prongay & Murray LLP, located at 1925 Century Park East, Suite 2100, Los Angeles California 90067. Interested parties can also contact the firm via email or telephone, with details provided on the firm’s website.
It’s important to note that becoming a member of this class action does not require immediate action. Investors may choose to retain their own legal representation or opt to stay as an absent member of the class action. This press release serves solely as Attorney Advertising and does not imply any guarantee of outcomes or results. For more details and updates, interested parties are encouraged to visit the Glancy Prongay & Murray LLP website.